New Mounjaro: separating the changes from the noise

The biggest misconception: a "new Mounjaro" isn't a different medicine

The phrase circulating online implies Eli Lilly has released a reformulated or upgraded product. It hasn't. Mounjaro is still tirzepatide — a dual GIP and GLP-1 receptor agonist that works by activating two gut-hormone pathways involved in appetite regulation and blood-sugar control. The six UK strengths (2.5, 5, 7.5, 10, 12.5 and 15mg), the pre-filled KwikPen and the once-weekly subcutaneous injection schedule are all unchanged. If you've read about a "new" version, the story is almost certainly about the context surrounding the medicine rather than the medicine itself. That's a meaningful distinction, because what has changed around Mounjaro over the past year matters quite a lot for anyone considering it.

The full overview of tirzepatide covers the mechanism and clinical evidence in detail, including the SURMOUNT-1 trial results, where average body-weight reduction reached around 20–21% over 72 weeks at the highest dose. Those figures haven't changed because the medicine hasn't changed.

If you want to understand what's new in this space, our new tirzepatide page brings together the latest developments around the treatment, from regulatory updates to what's on the horizon. What people looking for "mounjaro new" are most often tracking (correctly) is the rapid shift in rules, pricing and availability. Those genuinely have moved.

What has actually changed: rules, prices and NHS access

Three real developments are worth understanding together. First, prescribing rules for online services were tightened in 2024 and 2025. The updated Mounjaro prescribing rules now require, among other things, live weight verification rather than self-reporting, a change that affects which online providers can legally continue supplying these medicines. Providers who bypass this step are operating outside current GPhC guidance.

Second, NHS eligibility has expanded in phased steps. From June 2025, adults with a BMI of 40 or above and four or more qualifying weight-related conditions (from a list including type 2 diabetes, high blood pressure, dyslipidaemia, cardiovascular disease and obstructive sleep apnoea) became eligible through GP practices enrolled in the new 2026/27 contract. A second cohort (BMI 35–39.9 with four or more of those conditions) became eligible from 23 June 2026. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. Meeting the criteria doesn't guarantee access, as GP participation is optional and waiting lists exist. The latest Mounjaro news page tracks these developments as they happen.

Third, and most immediately felt by anyone already on treatment, Eli Lilly raised Mounjaro's UK list price from 1 September 2025, the highest-dose pen's list price rose from around £122 to around £330 for a four-week supply. Private market prices since then have typically ranged from roughly £149 to £375 per month depending on dose and provider, as widely reported at the time. If you're thinking about cost, the Mounjaro cost guide sets out what drives those differences and what a legitimate price should include.

The safety update you may have missed

One genuinely important piece of new information: in January 2026 the MHRA issued a Drug Safety Update for GLP-1 medicines (including tirzepatide) highlighting acute pancreatitis as a known but infrequent side effect that can be serious. The message to patients is straightforward: severe, persistent stomach pain that spreads towards the back, with or without vomiting, needs urgent medical attention. This doesn't mean pancreatitis is common, but it does mean it's a symptom to take seriously rather than assuming it's ordinary nausea.

The broader side-effect profile of Mounjaro (nausea, loose stools, constipation, indigestion, fatigue in the early weeks of treatment or after a dose step) remains the same as it was at launch. These effects are typically most noticeable shortly after starting or moving up a dose, and they settle for most people within a few days to a couple of weeks. The MHRA Drug Safety Updates page is the best place to check for any new communications, and patients can report suspected side effects at any time through the Yellow Card scheme.

If you're a patient who has already transferred to a new provider following the prescribing rule changes, the guide to starting again under the new rules explains what evidence you'll need and what the process looks like.

What stays the same: the clinical assessment requirement

We hear from a lot of people who are frustrated, either by NHS waiting times, by a provider that's stopped supplying them, or simply by how much the rules seem to have shifted in a short space of time. That's understandable. The one thing that hasn't changed, and won't, is the legal framework: Mounjaro is a Prescription-Only Medicine, which means a qualified prescriber has to assess your health and decide whether it's appropriate for you before any supply can happen.

That clinical review is also where the new prescribing rules are most relevant for patients. Providers operating to current GPhC standards will verify your identity, confirm your weight on a live video call rather than asking you to self-report, and review your medical history before prescribing. At nume, a GPhC-registered Independent Prescriber reads every consultation personally on the day it's submitted, the same standard applies to new patients and to people requesting a repeat. For anyone curious about our clinical team's approach, the clinical team profile sets out the oversight structure in detail.

Eligibility for private treatment follows the licensed criteria: adults aged 18 or over with a BMI of 30 or above, or 27 or above with at least one weight-related health condition. BMI alone doesn't decide the outcome, the prescriber considers the whole picture. If you'd like to find out whether Mounjaro is suitable for you, the free consultation is the place to start; there's no obligation and no fee for the clinical review itself.